GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Obeldesivir in Children and Adolescents With COVID-19
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT05996744
- Locations
- 🇺🇸
UF Health- Shands Hospital, Gainesville, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Trinity Clinical Research, LLC, Centreville, Alabama, United States
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Conditions
- Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 654
- Registration Number
- NCT05840211
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇲🇽Centro de Atención e Investigación Clínica en Oncología, Yucatán, Mexico
🇵🇱Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, Poland
Study of GS-4528 in Adults With Solid Tumors
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 132
- Registration Number
- NCT05840224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸The University of Washington/FHCC, Seattle, Washington, United States
🇪🇸START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I, Madrid, Spain
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Biological: Placebo for GS-6779Biological: Placebo for GS-2829
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05770895
- Locations
- 🇨🇳
St. Martin De Porres Hospital, Chiayi City, Taiwan
🇨🇳E-DA Hospital, Kaohsiung City, Taiwan
🇨🇳Chia-Yi Christian Hospital, Chiayi City, Taiwan
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT05765344
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT05760300
- Locations
- 🇺🇸
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05729568
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
🇺🇸Can Community Health Care, Fort Lauderdale, Florida, United States
🇺🇸Emory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT05718700
- Locations
- 🇫🇷
CHU Grenoble Alpes, Grenoble, France
🇷🇴Fundeni Clinical Institute, Bucharest, Romania
🇦🇹Medizinische Universität Graz Universitätsklinik für Innere Medizin, Klinische Abteilung für Gastroenterologie und Hepatologie, Graz, Austria
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2011
- Registration Number
- NCT05715528
- Locations
- 🇺🇸
Innovative Health, Hollywood, Florida, United States
🇺🇸Palm Springs Community Health Center, Miami Lakes, Florida, United States
🇺🇸Institute for Liver Health dba Arizona Clinical Trials, Chandler, Arizona, United States
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT05676931
- Locations
- 🇫🇷
Institut De Cancerologie Strasbourg Europe ICANS, Strasboug, France
🇫🇷Hopital FOCH, Suresnes, France
🇵🇱Medpolonia Sp. Z.o.o., Poznan, Poland